CCR2-

Hyun Sik Na1, Seon-Young Lee1, Dong Hwan Lee2

  • 1Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

Immune network
|July 7, 2025
PubMed
概括

可溶性C-C化基因受体2型 (sCCR2) 表达干细胞 (sCEMs) 通过抑制MCP-1,减少疼痛和保护软骨,提供优越的关节炎治疗. 这种基因疗法对OA具有显著的治疗潜力.